Lilly shares jump as analysts see retatrutide data extending obesity market edge
June 8 (Reuters) - Eli Lilly shares jumped 4% premarket on Monday, driven by compelling new data for its next-generation obesity drug, retatrutide, with analysts and investors expecting it to extend the drugmaker's lead in the booming weight-loss market. 
